Summary
Researchers evaluated the polypharmaceutical formulation NAMIG-5 for the control of type 2 diabetes, a global health challenge. In a model of diabetes induced by nicotinamide and streptozotocin, NAMIG-5 demonstrated significant antihyperglycemic activity without acute or subchronic toxicity. A randomized clinical trial with 90 participants showed significant reductions in fasting and postprandial glucose levels, as well as improvements in the lipid profile, surpassing the efficacy of metformin (p < 0.05). The formulation acts by inhibiting the aggregation of the amyloid polypeptide of human islets, with bioactive fractions identified as key constituents. These findings position NAMIG-5 as a safe therapeutic candidate for type 2 diabetes, offering a complementary approach to conventional therapies.
Key points
- NAMIG-5 significantly reduced fasting and postprandial glucose compared to metformin.
- The formulation showed no acute or subchronic toxicity in experimental models.
- The components of NAMIG-5 inhibit the aggregation of the amyloid polypeptide of human islets, a relevant mechanism in type 2 diabetes.
- The study involved 90 participants, demonstrating good tolerability and efficacy.
- Phytochemical analyses confirmed the authenticity and chemical consistency of the formulation.
✦ For you
If you have type 2 diabetes, consider observing how your diet and lifestyle impact your glucose levels. Try to include more whole foods and fiber-rich foods, which can help in glycemic control. Additionally, keep a diary of your glucose levels to identify patterns. If symptoms persist, seek a qualified healthcare professional.
For practitionersExpand
When considering NAMIG-5 for patients with type 2 diabetes, evaluate the possibility of integrating it into existing protocols, especially in cases where metformin is not well tolerated. The formulation may be a safe and effective option, but it is important to monitor the patient's response and adjust the approach as necessary.